Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.47 |
| ▸ | HTR2A | P28223 | 10/20 | 0.47 |
| ▸ | HTR2B | P41595 | 10/20 | 0.47 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.38 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.38 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.38 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.38 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.38 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.38 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.38 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.38 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.34 |
| ▸ | HTR3A | P46098 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2999672 | 0.98 | HTR2C (0.46) | HTR2CHTR2AHTR2BADCY6ADCY3 | |
| SCHEMBL1868771 | 0.84 | — | — | |
| SCHEMBL13540 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL8437491 | 0.83 | PNMT (0.43) | HTR2CHTR2AHTR2BPNMTCD44 | |
| Hydrochloric Acid SCHEMBL2720370 | 0.83 | PNMT (0.43) | HTR2CHTR2AHTR2BGID4PNMT | |
| SCHEMBL18576433 | 0.78 | — | — | |
| SCHEMBL72251 | 0.73 | — | — | |
| SCHEMBL3227687 | 0.73 | — | — | |
| SCHEMBL6423927 | 0.72 | PNMT (0.41) | HTR2CHTR2AHTR2BGID4PNMT | |
| SCHEMBL9123557 | 0.71 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6407112-B1 | 2A,3,4,5-TETRAHYDRO-1H-BENZ(CD)INDOL-2-ONE DERIVATIVES; 5-HYDROXYTRYPTAMINE AGONISTS; SLEEP, CIRCADIAN RHYTHYM, BIPOLAR, AND PSYCHOLOGICAL DISORDER TREATMENT | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1081136-A1 | OPTICALLY ACTIVE TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-5998433-A | THERAPY FOR HYPERLIPIDEMIA; ATHEROSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1160403-A | Substd. heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785939-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | HTR2C 2549/4885HTR2A 3002/4885HTR2B 3893/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | HTR2C 2549/4885HTR2A 3002/4885HTR2B 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.